CrushSCI.com
提供学术论文选刊润色服务
EXPERT OPINION ON INVESTIGATIONAL DRUGS 期刊封面 医学
返回期刊列表

Review Cycle Records

EXPERT OPINION ON INVESTIGATIONAL DRUGS

Taylor & Francis SCIE 非OA
2026新锐 3区2025中科院 3区2025 JCR Q1
134.9平均天数
131中位天数
45最短天数
334最长天数
842025发文量

Paper Review Records

全部论文审稿周期

13 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

111 天

Peripheral cannabinoid-1 receptor antagonists in clinical development: therapeutic potential for the management of obesity and related metabolic disorders

作者Jonanne Talebloo; Esha Chawla; Donya Shahamati; Swas Shiv; Kishore M. Gadde

作者单位1. University of California Irvine School of Medicine; 2. Vanderbilt University School of Medicine; 3. University of California Irvine; 4. Boston University

PDF源文件 DOI 网页
131 天

Taxane therapy in mCRPC: current positioning and emerging strategies to overcome resistance

作者Ling Wang; Yanfeng Tang; Mingsheng Liu; Hongqing Zhou; Hao Zeng; Bo Tang

作者单位1. Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University; 2. Qujing Affiliated Hospital of Kunming Medical University

PDF源文件 DOI 网页
45 天

Cognitive-enhancing drugs in Phase II clinical trials for Alzheimer’s disease: emerging therapeutic candidates

作者Patricia Regina Manzine; Marina Carrasco; Thaís Antonia Alves Fernandes; Suelen Santos Alves; Laura Guzman; Leila Driouech; Mireia Millet-Sigalat; Norberto Garcia Cairasco; Jordi Olloquequi; M. Emilia Juan; Miren Ettcheto; Marcia Regina Cominetti; Antoni Camins

作者单位1. University of Barcelona; 2. Instituto de Salud Carlos III; 3. Institut d’Investigació Sanitària Pere Virgili (IISPV); 4. Federal University of São Carlos; 5. University of São Paulo; 6. Universidad Autónoma de Chile; 7. Trinity College Dublin

PDF源文件 DOI 网页
153 天

Budigalimab: a viable option for patients with advanced solid tumors

作者Alice Mogenet; Laurent Greillier

作者单位1. Aix Marseille University, APHM, INSERM, CNRS, CRCM

PDF源文件 DOI 网页
47 天

Lonvoguran ziclumeran: a CRISPR-CAS9-based gene therapy for the treatment of hereditary angioedema

作者Long Hoang Luong; Shane Stone; Van Bui; Bharosha Bhattarai; Mai Thi Vu; E. Pelinsu Aydin; Timothy Craig

作者单位1. Kansai Medical University; 2. Hanoi Medical University; 3. Penn State Health; 4. Vinmec Times City International Hospital and Vinmec-VinUni Institute of Immunology, VinUniversity; 5. University of Health Sciences İzmir

PDF源文件 DOI 网页
219 天

Investigational IL-17A antagonist in the treatment of psoriatic arthritis - a review

作者Osariemen Osunbor; Jan René Nkeck; Adewale O. Adebajo

作者单位1. Barnsley Hospital NHS Foundation Trust; 2. University of Yaoundé I; 3. University of Sheffield

PDF源文件 DOI 网页
159 天

Vidofludimus calcium for the treatment of multiple sclerosis: development rationale, mechanism of action, and early trial data

作者Matej Ondrus; Robert J. Fox; Evelyn Peelen; Juliano Fonseca; Valentina Sciacca; Ines Sanchez-Gomez; Jacques Arend; Alexandra Herrmann; Maria Samcova; Christian Gege; Lesia Havrylova; Hella Kohlhof; Jason Tardio; Daniel Vitt; Andreas Muehler

作者单位1. Immunic AG; 2. Cleveland Clinic

PDF源文件 DOI 网页
161 天

Advancements in longevity pharmacology research – are we finally seeing clinical progression?

作者Madia Lozupone

作者单位1. University of Bari Aldo Moro; 2. Azienda Sanitaria Locale (ASL) Bari

PDF源文件 DOI 网页
131 天

Targeting fatty acid synthase inhibitors for the treatment of acne vulgaris: what can we learn from early phase investigations

作者Dániel Törőcsik; Dóra Tiszai; Christos C. Zouboulis

作者单位1. University of Debrecen; 2. HUN-REN-UD Allergology Research Group; 3. University Pharmacy, Clinical Centre, University of Debrecen; 4. Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg

PDF源文件 DOI 网页
69 天

Elezanumab for the treatment of spinal cord injury: assessing the clinical development journey to date

作者Andrea J. Mothe; Philippe P. Monnier; Charles H. Tator; Michael G. Fehlings

作者单位1. Krembil Brain Institute & University Health Network; 2. University of Toronto

PDF源文件 DOI 网页

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿96.4 天

中位数77 天

Contact CrushSCI

联系 CrushSCI

扫码添加微信,或留下手机号/微信号,我们将与你确认稿件阶段、编辑需求和投稿计划。

当前选择:论文编辑服务

也可以预留联系方式

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。